CSPC's EGFR-targeting ADC SYS6010 showed favorable efficacy in Phase I, especially in patients with EGFR-mutant NSCLC who were resistant to previous EGFR-TKI treatments. (Shutterstock)
Keep up with the top pharma business news of the week. On the go.
